Literature DB >> 20848492

Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray.

Seungha Kang1, Stuart E Denman, Mark Morrison, Zhongtang Yu, Joel Dore, Marion Leclerc, Chris S McSweeney.   

Abstract

BACKGROUND: A custom phylogenetic microarray composed of small subunit ribosomal RNA probes, representing ≈500 bacterial species from the human and animal gut, was developed and evaluated for analysis of gut microbial diversity using fecal samples from healthy subjects and Crohn's disease (CD) patients.
METHODS: Oligonucleotide probes (≈40 mer) used on the microarray were selected from published articles or designed with the "GoArray" microarray probe design program using selected bacterial 16S rRNA sequences. Fecal 16S rDNA from individual samples of six healthy subjects and six CD patients were used as template to generate fluorescently labeled cRNA that was hybridized to the microarray. Differences revealed by the microarray in relative abundance of microbial populations between healthy and diseased patients were verified using quantitative real-time polymerase chain reaction (PCR) with species-specific primer sets.
RESULTS: The microarray analyses showed that Eubacterium rectale, Bacteroides fragilis group, B. vulgatus, Ruminococcus albus, R. callidus, R. bromii, and Faecalibacterium prausnitzii were 5-10-fold more abundant in the healthy subjects than in the CD patients, while Enterococcus sp., Clostridium difficile, Escherichia coli, Shigella flexneri, and Listeria sp. were more abundant in the CD group.
CONCLUSIONS: The microarray detected differences in abundance of bacterial populations within the phylum Firmicutes that had been reported previously for the same samples based on phylogenetic analysis of metagenomic clone libraries. In addition, the microarray showed that Enterococcus sp. was in higher abundance in the CD patients. This microarray should be another useful tool to examine the diversity and abundance of human intestinal microbiota.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848492     DOI: 10.1002/ibd.21319

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  151 in total

1.  Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection.

Authors:  C A Duplessis; D You; M Johnson; A Speziale
Journal:  Infection       Date:  2011-12-08       Impact factor: 3.553

Review 2.  The transition of acute to chronic bowel inflammation in spondyloarthritis.

Authors:  Liesbet Van Praet; Peggy Jacques; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2012-04-17       Impact factor: 20.543

Review 3.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

4.  The effects from DNA extraction methods on the evaluation of microbial diversity associated with human colonic tissue.

Authors:  Páraic Ó Cuív; Daniel Aguirre de Cárcer; Michelle Jones; Eline S Klaassens; Daniel L Worthley; Vicki L J Whitehall; Seungha Kang; Christopher S McSweeney; Barbara A Leggett; Mark Morrison
Journal:  Microb Ecol       Date:  2010-12-14       Impact factor: 4.552

Review 5.  Application of computational methods in genetic study of inflammatory bowel disease.

Authors:  Jin Li; Zhi Wei; Hakon Hakonarson
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 6.  Impact of the gut microbiome on mucosal inflammation.

Authors:  Warren Strober
Journal:  Trends Immunol       Date:  2013-08-16       Impact factor: 16.687

7.  Feed your gut with caution!

Authors:  Vishal Singh; Beng San Yeoh; Matam Vijay-Kumar
Journal:  Transl Cancer Res       Date:  2016-09       Impact factor: 1.241

8.  Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2.

Authors:  Nitsan Maharshak; Eun Young Huh; Chorlada Paiboonrungruang; Michael Shanahan; Lance Thurlow; Jeremy Herzog; Zorka Djukic; Roy Orlando; Rafal Pawlinski; Melissa Ellermann; Luke Borst; Siten Patel; Iris Dotan; Ryan B Sartor; Ian M Carroll
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

Review 9.  The gut microbiota in IBD.

Authors:  Chaysavanh Manichanh; Natalia Borruel; Francesc Casellas; Francisco Guarner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-08-21       Impact factor: 46.802

10.  Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung's disease.

Authors:  Joseph F Pierre; Amanda J Barlow-Anacker; Christopher S Erickson; Aaron F Heneghan; Glen E Leverson; Scot E Dowd; Miles L Epstein; Kenneth A Kudsk; Ankush Gosain
Journal:  J Pediatr Surg       Date:  2014-08       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.